A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Osteoarthritis of the Knee

In brief

This is a double-blind, prospective, randomized study in which patients will be randomized to 1 of 4 treatment arms (3 active and 1 placebo). Each patient will receive two doses of active medication or placebo, with study drug administered intravenously (IV). The primary goal of the study is to assess the safety and tolerability of repeat administrations of REGN475 compared to placebo in patients with osteoarthritis (OA) of the knee.

Key facts

Study ID

NCT00944892

Run by

Regeneron Pharmaceuticals

People needed

200

Starts

2009-08-01

Expected to finish

2010-05-01

Last updated by the study team

2011-12-08

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women ≥ 40 and ≤ 75 years of age.
• Diagnosis of OA of the knee according to American College of Rheumatology (ACR) criteria, and experiencing moderate to severe pain in the index knee for at least 3 months prior to the screening visit.
• Kellgren-Lawrence grade 2-3 radiographic severity of the index knee at or within 6 months prior to Screening.

You may not qualify if…

• Significant concomitant illness including, but not limited to, cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease that would adversely affect the patient's participation in the study.
• Patients with joint replacement in the affected knee.
• Patients with peripheral neuropathy due to any reason.

Where it is running

• Study site — Anaheim, California, United States
• Study site — Tampa, Florida, United States
• Study site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.